InsidersTradesSigma
Follow the Arbutus Biopharma Corporation stock price and the full management transaction log of the company, a listed issuer based in Canada. Shares trade on the CA market, under the oversight of SEDI. Market capitalisation: €985.3m. The latest transaction was reported on 11 June 2026 (50 - Grant of options). Among the most active insiders: Sawhney, Roger. The full history is free.
Analysts rate Arbutus Biopharma Corporation Strong Buy (bullish), based on 1 analysts. Average price target: US$5.53.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
Arbutus Biopharma Corporation es una empresa biofarmacéutica centrada en el desarrollo de tratamientos para infecciones virales, particularmente la hepatitis B. Cotiza en la Bolsa de Toronto bajo el símbolo ABUS.